Qiagen gets ex-U.S. commercialization rights to NeuMoDx's PCR systems

NeuMoDx Molecular Inc. (Ann Arbor, Mich.) granted Qiagen N.V. (Xetra:QIA; NYSE:QGEN) rights to commercialize NeuMoDx 288 and 96 PCR automation systems outside of the U.S., where NeuMoDx will commercialize the products. Qiagen, which holds about a 19.9% stake in NeuMoDx, will also have the right to acquire all NeuMoDx shares it does not own for $234 million...